Research Progress of Macropinocytosis in Digestive System Tumors

CHEN Ting; YAN Shuguang; LI Jingtao; WEI Hailiang; ZHOU Yongxue

doi:10.3971/j.issn.1000-8578.2023.22.1079

Cancer Research on Prevention and Treatment > 2023 > 50(4): 401-407. > DOI: 10.3971/j.issn.1000-8578.2023.22.1079

CHEN Ting, YAN Shuguang, LI Jingtao, WEI Hailiang, ZHOU Yongxue. Research Progress of Macropinocytosis in Digestive System Tumors[J]. Cancer Research on Prevention and Treatment, 2023, 50(4): 401-407. DOI: 10.3971/j.issn.1000-8578.2023.22.1079

Citation:

PDF (2449 KB)

Research Progress of Macropinocytosis in Digestive System Tumors

CHEN Ting^{1, 2,},
YAN Shuguang^{1, 2},
LI Jingtao³,
WEI Hailiang⁴,
ZHOU Yongxue^{1, 2, , ,}

1.
Teaching and Research Department of Gastroenterology, School of Basic Medicine, Shaanxi University of Chinese Medicine, Xianyang 712046, China
2.
Shaanxi Provincial Key Laboratory of Gastrointestinal Disease and Syndrome Formulae, Xianyang 712046, China
3.
First Department of Hepatology, The Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang 712046, China
4.
First Departments of General Surgery, The Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang 712046, China

Funding:

National Natural Science Foundation of China 81403320

National Natural Science Foundation of China 81873233

Discipline Innovation Team Construction Project of Shaanxi University of Chinese Medicine 2019-YL-05

More Information

Corresponding author:
ZHOU Yongxu, E-mail: zhou8521@163.com
Received Date: September 15, 2022
Revised Date: January 05, 2023
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Macropinocytosis, an evolutionarily conserved, actin-dependent form of endocytosis, is involved in various physiological processes, including nutrient absorption, antigen presentation, and cell signaling transduction and migration. Oncogene activation and tumor suppressor inactivation induce macropinocytosis in tumors in the digestive system, involved in tumorigenesis and progression, whereas the inhibition of macropinocytosis slows the aggressive phenotype of digestive system tumors and improves the efficacy of anti-tumor drugs. Macropinocytosis can also be used as a delivery route for anti-tumor drugs. Therefore, macropinocytosis has been widely studied to develop new methods for the treatment of digestive system tumors.This paper reviews the role of macropinocytosis in the body, the regulation of macropinocytosis-related signaling pathway, as well as the mechanism of macropinocytosis in colorectal cancer, pancreatic ductal adenocarcinoma, liver cancer and other digestive system tumors, to provide reference for related researches.
- Micropinocytosis,
- Digestive system tumors,
- Signal pathway

FullText(HTML)

Competing interests: The authors declare that they have no competing interests.

References (49)

References

[1]	Mima K, Kosumi K, Baba Y, et al. The microbiome, genetics, and gastrointestinal neoplasms: the evolving field of molecular pathological epidemiology to analyze the tumor-immune-microbiome interaction[J]. Hum Genet, 2021, 140(5): 725-746. doi: 10.1007/s00439-020-02235-2
[2]	Ha KD, Bidlingmaier SM, Liu B. Macropinocytosis Exploitation by Cancers and Cancer Therapeutics[J]. Front Physiol, 2016, 7: 381.
[3]	Kerr MC, Teasdale RD. Defining macropinocytosis[J]. Traffic, 2009, 10(4): 364-371. doi: 10.1111/j.1600-0854.2009.00878.x
[4]	Palm W. Metabolic functions of macropinocytosis[J]. Philos Trans R Soc Lond B Biol Sci, 2019, 374(1765): 20180285. doi: 10.1098/rstb.2018.0285
[5]	Lin XP, Mintern JD, Gleeson PA. Macropinocytosis in Different Cell Types: Similarities and Differences[J]. Membranes (Basel), 2020, 10(8): 177. doi: 10.3390/membranes10080177
[6]	姜萱璟, 张伟晴, 贺丽娜, 等. 巨胞饮作用及其对脑胶质瘤的影响[J]. 现代肿瘤医学, 2021, 29(20): 3668-3672. doi: 10.3969/j.issn.1672-4992.2021.20.034 Jiang XJ, Zhang WQ, He LN, et al. Macropinocytosis and its influence on glioblastoma[J]. Xian Dai Zhong Liu Yi Xue, 2021, 29(20): 3668-3672. doi: 10.3969/j.issn.1672-4992.2021.20.034
[7]	Finicle BT, Jayashankar V, Edinger AL. Nutrient scavenging in cancer[J]. Nat Rev Cancer, 2018, 18(10): 619-633. doi: 10.1038/s41568-018-0048-x
[8]	Commisso C. The pervasiveness of macropinocytosis in oncological malignancies[J]. Philos Trans R Soc Lond B Biol Sci, 2019, 374(1765): 20180153. doi: 10.1098/rstb.2018.0153
[9]	Colin M, Delporte C, Janky R, et al. Dysregulation of Macropinocytosis Processes in Glioblastomas May Be Exploited to Increase Intracellular Anti-Cancer Drug Levels: The Example of Temozolomide[J]. Cancers (Basel), 2019, 11(3): 411. doi: 10.3390/cancers11030411
[10]	Jayashankar V, Edinger AL. Macropinocytosis confers resistance to therapies targeting cancer anabolism[J]. Nat Commun, 2020, 11(1): 1121. doi: 10.1038/s41467-020-14928-3
[11]	Ramirez C, Hauser AD, Vucic EA, et al. Plasma membrane V-ATPase controls oncogenic RAS-induced macropinocytosis[J]. Nature, 2019, 576(7787): 477-481. doi: 10.1038/s41586-019-1831-x
[12]	Unni AM, Lockwood WW, Zejnullahu K, et al. Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma[J]. Elife, 2015, 4: e06907. doi: 10.7554/eLife.06907
[13]	Commisso C, Davidson SM, Soydaner-Azeloglu RG, et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells[J]. Nature, 2013, 497(7451): 633-637. doi: 10.1038/nature12138
[14]	Palm W, Araki J, King B, et al. Critical role for PI3-kinase in regulating the use of proteins as an amino acid source[J]. Proc Natl Acad Sci U S A, 2017, 114(41): E8628-E8636.
[15]	Bar-Sagi D, Feramisco JR. Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins[J]. Science, 1986, 233(4768): 1061-1068. doi: 10.1126/science.3090687
[16]	Zwartkruis FJT, Burgering BMT. Ras and macropinocytosis: trick and treat[J]. Cell Res, 2013, 23(8): 982-983. doi: 10.1038/cr.2013.79
[17]	Amyere M, Payrastre B, Krause U, et al. Constitutive macropinocytosis in oncogene-transformed fibroblasts depends on sequential permanent activation of phosphoinositide 3-kinase and phospholipase C[J]. Mol Biol Cell, 2000, 11(10): 3453-3467. doi: 10.1091/mbc.11.10.3453
[18]	Lee SW, Zhang Y, Jung M, et al. EGFR-Pak Signaling Selectively Regulates Glutamine Deprivation-Induced Macropinocytosis[J]. Dev Cell, 2019, 50(3): 381-392.e5. doi: 10.1016/j.devcel.2019.05.043
[19]	Liu H, Sun M, Liu Z, et al. KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs[J]. J Control Release, 2019, 296: 40-53. doi: 10.1016/j.jconrel.2019.01.014
[20]	Redelman-Sidi G, Iyer G, Solit DB, et al. Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells[J]. Cancer Res, 2013, 73(3): 1156-1167. doi: 10.1158/0008-5472.CAN-12-1882
[21]	Takenaka T, Nakai S, Katayama M, et al. Effects of gefitinib treatment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell lung cancer cells[J]. Int J Pharm, 2019, 572: 118762. doi: 10.1016/j.ijpharm.2019.118762
[22]	Zdżalik-Bielecka D, Poświata A, Kozik K, et al. The GAS6-AXL signaling pathway triggers actin remodeling that drives membrane ruffling, macropinocytosis, and cancer-cell invasion[J]. Proc Natl Acad Sci U S A, 2021, 118(28): e2024596118. doi: 10.1073/pnas.2024596118
[23]	Redelman-Sidi G, Binyamin A, Gaeta I, et al. The Canonical Wnt Pathway Drives Macropinocytosis in Cancer[J]. Cancer Res, 2018, 78(16): 4658-4670. doi: 10.1158/0008-5472.CAN-17-3199
[24]	Ghoshal P, Singla B, Lin H, et al. Nox2-Mediated PI3K and Cofilin Activation Confers Alternate Redox Control of Macrophage Pinocytosis[J]. Antioxid Redox Signal, 2017, 26(16): 902-916. doi: 10.1089/ars.2016.6639
[25]	Sivanand S, Vander Heiden MG. Transcriptional activation of macropinocytosis by the Hippo pathway following nutrient limitation[J]. Genes Dev, 2020, 34(19-20): 1253-1255. doi: 10.1101/gad.343632.120
[26]	Srivastava RK, Li C, Khan J, et al. Combined mTORC1/mTORC2 inhibition blocks growth and induces catastrophic macropinocytosis in cancer cells[J]. Proc Natl Acad Sci U S A, 2019, 116(49): 24583-24592. doi: 10.1073/pnas.1911393116
[27]	Dai M, Yan G, Wang N, et al. In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy[J]. Nat Commun, 2021, 12(1): 3055. doi: 10.1038/s41467-021-23316-4
[28]	Palm W, Park Y, Wright K, et al. The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1[J]. Cell, 2015, 162(2): 259-270. doi: 10.1016/j.cell.2015.06.017
[29]	Zhu G, Pei L, Xia H, et al. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer[J]. Mol Cancer, 2021, 20(1): 143. doi: 10.1186/s12943-021-01441-4
[30]	Hanada K, Kawada K, Nishikawa G, et al. Dual blockade of macropinocytosis and asparagine bioavailability shows synergistic anti-tumor effects on KRAS-mutant colorectal cancer[J]. Cancer Lett, 2021, 522: 129-141. doi: 10.1016/j.canlet.2021.09.023
[31]	Costa Verdera H, Gitz-Francois JJ, Schiffelers RM, et al. Cellular uptake of extracellular vesicles is mediated by clathrin-independent endocytosis and macropinocytosis[J]. J Control Release, 2017, 266: 100-108. doi: 10.1016/j.jconrel.2017.09.019
[32]	Takakura H, Nakao T, Narita T, et al. Citrus limonL. -Derived Nanovesicles Show an Inhibitory Effect on Cell Growth in p53-Inactivated Colorectal Cancer Cells via the Macropinocytosis Pathway[J]. Biomedicines, 2022, 10(6): 1352. doi: 10.3390/biomedicines10061352
[33]	Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu; Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma[J]. Cancer Cell, 2017, 32(2): 185-203.e13. doi: 10.1016/j.ccell.2017.07.007
[34]	Encarnación-Rosado J, Kimmelman AC. Harnessing metabolic dependencies in pancreatic cancers[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(7): 482-492. doi: 10.1038/s41575-021-00431-7
[35]	Rai V, Agrawal S. Targets (Metabolic Mediators) of Therapeutic Importance in Pancreatic Ductal Adenocarcinoma[J]. Int J Mol Sci, 2020, 21(22): 8502. doi: 10.3390/ijms21228502
[36]	Xiong X, Rao G, Roy RV, et al. Ubiquitin-binding associated protein 2 regulates KRAS activation and macropinocytosis in pancreatic cancer[J]. FASEB J, 2020, 34(9): 12024-12039. doi: 10.1096/fj.201902826RR
[37]	Thu PM, Zheng ZG, Zhou YP, et al. Phellodendrine chloride suppresses proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis[J]. Eur J Pharmacol, 2019, 850: 23-34. doi: 10.1016/j.ejphar.2019.01.060
[38]	Zhang YF, Li Q, Huang PQ, et al. A low amino acid environment promotes cell macropinocytosis through the YY1-FGD6 axis in Ras-mutant pancreatic ductal adenocarcinoma[J]. Oncogene, 2022, 41(8): 1203-1215. doi: 10.1038/s41388-021-02159-9
[39]	Ikeda M, Okusaka T, Mitsunaga S, et al. Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma[J]. Clin Cancer Res, 2016, 22(6): 1385-1394. doi: 10.1158/1078-0432.CCR-15-1354
[40]	Zhang MS, Cui JD, Lee D, et al. Hypoxia-induced macropinocytosis represents a metabolic route for liver cancer[J]. Nat Commun, 2022, 13(1): 954. doi: 10.1038/s41467-022-28618-9
[41]	Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma[J]. Gastro-enterology, 2019, 156(2): 477-491.e1. doi: 10.1053/j.gastro.2018.08.065
[42]	Byun JK, Lee S, Kang GW, et al. Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2022, 41(1): 98. doi: 10.1186/s13046-022-02296-3
[43]	Demarest CT, Chang AC. The Landmark Series: Multimodal Therapy for Esophageal Cancer[J]. Ann Surg Oncol, 2021, 28(6): 3375-3382. doi: 10.1245/s10434-020-09565-5
[44]	He S, Zhao C, Tao H, et al. A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer[J]. Drug Deliv, 2022, 29(1): 1243-1256. doi: 10.1080/10717544.2022.2063454
[45]	Jiang Y, Guo H, Tong T, et al. lncRNA lnc-POP1-1 upregulated by VN1R5 promotes cisplatin resistance in head and neck squamous cell carcinoma through interaction with MCM5[J]. Mol Ther, 2022, 30(1): 448-467. doi: 10.1016/j.ymthe.2021.06.006
[46]	Song S, Xia X, Qi J, et al. Silmitasertib-induced macropinocytosis promoting DDP intracellular uptake to enhance cell apoptosis in oral squamous cell carcinoma[J]. Drug Deliv, 2021, 28(1): 2480-2494. doi: 10.1080/10717544.2021.2000677
[47]	Lu Y, Zheng Z, Yuan Y, et al. The Emerging Role of Exosomes in Oral Squamous Cell Carcinoma[J]. Front Cell Dev Biol, 2021, 9: 628103. doi: 10.3389/fcell.2021.628103
[48]	Cao J, Zhang M, Xie F, et al. Exosomes in head and neck cancer: Roles, mechanisms and applications[J]. Cancer Lett, 2020, 494: 7-16. doi: 10.1016/j.canlet.2020.07.005
[49]	Sasabe E, Tomomura A, Liu H, et al. Epidermal growth factor/epidermal growth factor receptor signaling blockage inhibits tumor cell-derived exosome uptake by oral squamous cell carcinoma through macropinocytosis[J]. Cancer Sci, 2022, 113(2): 609-621. doi: 10.1111/cas.15225

Cited By

Figures(1) / Tables(1)

Get Citation

PDF

XML

Article views (2179) PDF downloads (1303)

Turn off MathJax

Article Contents

Abstract

References

Research Progress of Macropinocytosis in Digestive System Tumors

Abstract

References

Catalog

Contact Us

Research Progress of Macropinocytosis in Digestive System Tumors

Abstract

References

Catalog

Contact Us

Export File

Citation

Format

Content